Madecassoside (Ursane Triterpene Saponin · Anti-inflammatory · Skin Repair · Cica)
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | Madecassoside |
| Chemical class | Terpenoid — Pentacyclic Triterpene Saponin (Ursane skeleton) |
| CAS | 34540-22-2 |
| Primary source | Centella asiatica (Gotu Kola / Pennywort) |
| Key applications | Anti-inflammatory, skin repair, collagen synthesis, neuroprotective |
| Claim strength | Moderate |
| Typical form | Centella asiatica TECA extract (30% madecassoside fraction); madecassoside isolate |
| Buy from Herbuno |
Name origin: From Madagascar — reflecting one of the geographic regions where Centella asiatica was intensively studied and from which some early botanical material was sourced. Madecassoside is the glycoside of madecassic acid (a C2-hydroxylated asiatic acid), and is the second major triterpene saponin in Centella asiatica after asiaticoside. Traditional use: Identical to asiaticoside — madecassoside co-occurs with asiaticoside in Centella asiatica preparations used across Ayurveda, TCM, and Southeast Asian traditions for wound healing, skin conditions, cognitive tonification, and venous health. Research trajectory: Madecassoside has attracted dedicated research for its potent anti-inflammatory activity (particularly in skin contexts), collagen synthesis stimulation, and neuroprotective properties. Comparative studies suggest madecassoside is the more anti-inflammatory fraction of the TECA complex (relative to asiaticoside which has slightly stronger collagen stimulation). Commercial source: Available as a constituent of Centella asiatica (Gotu Kola/Pennywort) extracts. See sourcing options below.
Evidence for Madecassoside Applications
Anti-inflammatory — skin and systemic: Madecassoside inhibits NF-κB and reduces TNF-α, IL-6, and IL-1β in macrophage and skin cell models with potency exceeding asiaticoside in parallel assays. In vivo anti-inflammatory efficacy confirmed in topical skin inflammation, colitis, and arthritis animal models. Considered the primary anti-inflammatory constituent of the TECA complex. Claim strength: Moderate.
Skin repair and collagen synthesis: Madecassoside stimulates collagen type I synthesis via TGF-β1/Smad pathway activation and promotes fibroblast migration and proliferation. Human clinical trials of topical Centella preparations (TECA) for wound healing, scar reduction, and stretch mark management include madecassoside as a primary active alongside asiaticoside. Claim strength: Moderate.
Neuroprotective: Madecassoside reduces amyloid-beta toxicity, inhibits neuroinflammation, and activates Nrf2 in neuronal models. Animal studies show improved cognitive function and reduced neurodegeneration markers. Claim strength: Moderate.
Antioxidant: Madecassoside activates Nrf2/HO-1 and catalase, reducing oxidative stress in cell models. The 2-OH substitution on the madecassic acid aglycone compared to asiatic acid may contribute to its enhanced antioxidant and anti-inflammatory activity. Claim strength: Moderate.
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Oral venous and cognitive applications: 60–120 mg/day total triterpenoids (TECA standard) delivers approximately 18–36 mg madecassoside (at 30% fraction). Topical skin repair: 1% TECA cream (containing ~0.3% madecassoside) applied twice daily is the standard specification for clinical wound healing data. For standalone madecassoside formulations, specify minimum 90% HPLC purity for isolate-grade material. Herbuno’s Centella extract products provide madecassoside as part of the total triterpenoid complex — request HPLC analysis for individual madecassoside quantification on CoA.
Frequently Asked Questions — Madecassoside
What is the difference between madecassoside and asiaticoside?
Madecassoside is the glycoside of madecassic acid; asiaticoside is the glycoside of asiatic acid. Madecassic acid has an additional hydroxyl group at C-2 compared to asiatic acid. This structural difference gives madecassoside greater anti-inflammatory potency (NF-κB inhibition) and enhanced Nrf2 activation relative to asiaticoside. Asiaticoside has slightly stronger direct collagen synthesis stimulation. In the TECA complex (which includes both), the combination provides synergistic wound healing and anti-inflammatory activity.
Why is madecassoside prominent in K-beauty formulations?
Korean cosmetic innovation has widely adopted “Cica” (Centella asiatica) as a functional skincare active. Madecassoside is particularly valued for its potent anti-inflammatory effect (reducing redness and irritation) and skin barrier repair activity, making it the preferred single-constituent claim for soothing and repair positioning in K-beauty. The compound is now specified by name in premium Korean cosmetic formulations as a differentiating technical claim, in contrast to generic “Centella extract” claims.
Can madecassoside be used in a post-procedure skincare product?
Yes — post-laser, post-chemical peel, and post-microneedling recovery formulations are a well-established application. Madecassoside’s anti-inflammatory activity reduces post-procedure redness and inflammation; asiaticoside/asiatic acid co-present in Centella extract stimulates collagen repair. Topical Centella preparations are used in professional skincare clinics across Asia for this application. Include at 0.5–2% total TECA (or equivalent calculated madecassoside) in a gentle, fragrance-free emulsion base.
Is madecassoside better than niacinamide for skin anti-inflammatory effects?
They address different mechanisms. Madecassoside is a direct NF-κB inhibitor reducing cytokine-driven inflammation; niacinamide (vitamin B3) reduces melanosome transfer (skin brightening), improves skin barrier function, and reduces sebum production. They are complementary rather than competitive. Combining madecassoside (anti-inflammatory, collagen repair) with niacinamide (barrier function, brightening, sebum regulation) creates a comprehensive multi-mechanism skin health formulation addressing inflammation, barrier, and pigmentation in parallel.
Related compounds: Asiaticoside, Centelloside, Oleanolic Acid, Ursolic Acid
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery